Search clinical trials for: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab

Total 110 results

University of Kansas Medical Center
Merck Sharp & Dohme LLC

Active, not recruiting

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

Adenocarcinoma | Stomach Cancer | Gastro Esophageal Junction Cancer

United States
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Hospital San Carlos, Madrid

Completed

"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".

Rectal Cancer Stage II | Rectal Cancer Stage III | Rectal Cancer, Adenocarcinoma | Distant Metastasis | Local Recurrence of Malignant Tumor of Rectum

Spain
Zhejiang Cancer Hospital

Unknown

Neoadjuvant Versus Adjuvant Therapy in Treating Resectable Thoracic Esophageal Cancer

Esophageal Cancer

China
Amsterdam UMC, location VUmc

Recruiting

COLLISION RELAPSE Trial

Recurrence | Colorectal Cancer | Surgery | Chemotherapy Effect | Liver Metastases | Liver Metastasis Colon Cancer

Netherlands
Weijing Sun, MD, FACP

Withdrawn

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Adenocarcinoma | Stomach Cancer

United States
Yonsei University

Not yet recruiting

Development of a Genome-based Platform for Personalized Treatment in Locally Advanced Rectal Cancer Patients

Locally Advanced Rectal Cancer

Korea, Republic of
Shanghai Zhongshan Hospital

Recruiting

Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma (OP-TNT)

Rectal Cancer

China
Sun Yat-sen University

Completed

Surgery Alone Versus Neoadjuvant Treatment Followed by Surgery For MRI-defined T3 Mid-low Rectal Cancer

Rectal Cancer
Medical University Innsbruck
Merck Sharp & Dohme LLC

Recruiting

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (INNWOP1)

Non Small Cell Lung Cancer

Austria
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; InSightec

Not yet recruiting

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Recurrent Glioblastoma

United States
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Jagiellonian University

Completed

Randomized Clinical Trial on Preoperative Radiotherapy 25 Gy in Rectal Cancer

Rectal Cancer

Poland
Zhejiang Cancer Hospital

Completed

Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer

Breast Cancer | HER2 | Preoperative Systemic Treatment
Mansoura University

Recruiting

Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy

Breast Cancer

Egypt
University of Texas Southwestern Medical Center

Recruiting

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Renal Cell Carcinoma

United States
Seoul National University Hospital

Completed

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

Pancreatic Cancer | Neoadjuvant
Tata Memorial Centre

Not yet recruiting

Study for Wait and Watch Suitable in Rectal Cancer (ARROW)

Rectal Neoplasms
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC (Modified)

Biliary Tract Neoplasms
Shanghai Zhongshan Hospital
RenJi Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaborators

Recruiting

Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Intrahepatic Cholangiocarcinoma | Lenvatinib | PD1 Antibody | Gemox Chemotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy (NeoIM-Lung)

NSCLC

China
Shanghai Zhongshan Hospital

Recruiting

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Neoadjuvant Chemoimmunotherapy

China
Craig L Slingluff, Jr

Recruiting

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101)

Pancreatic Cancer

United States
Shanghai Zhongshan Hospital
Shenzhen University General Hospital; Xuhui Central Hospital, Shanghai; Minhang... and other collaborators

Recruiting

PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors

Cholangiocarcinoma, Intrahepatic

China
University Hospital, Rouen
Federation Francophone de Cancerologie Digestive; UNICANCER; Federation of Research... and other collaborators

Unknown

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01)

Resectable Pancreatic Duct Adenocarcinoma

France
SCRI Development Innovations, LLC
Bristol-Myers Squibb; Genentech, Inc.

Completed

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Breast Cancer

United States
West China Hospital

Recruiting

Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors (TNTCRT)

Chemoradiotherapy | Total Neoadjuvant Treatment | Local Advanced Rectal Cancer | High Risk Factors

China
Sun Yat-sen University

Unknown

A Study of Anti-PD-1 Combinations of D-CIK Immunotherapy and Axitinib in Advanced Ranal Carcinoma

Renal Cancer Metastatic

China
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaborators

Recruiting

Clinical Treatments in Specialized Disease of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)

Glottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall Carcinoma

China
IFOM ETS - The AIRC Institute of Molecular Oncology

Active, not recruiting

Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA)

Colorectal Neoplasms | Microsatellite Instability

Italy
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC (BASKETⅡ)

Colorectal Cancer | Immunotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

Radiotherapy | Rectal Neoplasms Malignant

China
Celyad Oncology SA
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Unresectable Metastatic Colorectal Cancer

Belgium, United States
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
Peking Union Medical College Hospital

Recruiting

The Choice of Treatment Methods and Efficacy of LABC

Locally Advanced Breast Cancer

China
Trishula Therapeutics, Inc.
AbbVie

Completed

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Solid Tumor, Adult

United States, Korea, Republic of
Amany sayed Abass

Unknown

Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum

Rectal Adenocarcinoma

Egypt
Genome & Company
Merck Sharp & Dohme LLC

Recruiting

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
University Hospital, Linkoeping
The Swedish Research Council; Region Östergötland

Recruiting

Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement. (ABOGRAFT)

Prosthetic Joint Infection | Osteoarthritis, Hip | Antibiotic Resistant Infection | Arthroplasty, Replacement, Hip

Sweden
Targovax ASA

Terminated

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

Rectal Cancer

New Zealand, Australia
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

Colorectal Cancer | Multiple Cancer

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Colorectal Carcinoma
Kyungpook National University Hospital

Recruiting

Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer

Colon Cancer

Korea, Republic of
Ralf Hofheinz
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Deutsche... and other collaborators

Recruiting

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Rectal Cancer

Germany
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital; Curis, Inc.

Recruiting

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Stomach Cancer | Gastric Cancer | Esophageal Cancer | Gastroesophageal Junction Cancer | Esophagus Cancer

United States
Eye & ENT Hospital of Fudan University

Recruiting

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Oropharynx Carcinoma

China
Tianjin Medical University Cancer Institute and...
Shanxi Province Cancer Hospital; Cancer Institute and Hospital, Chinese Academy... and other collaborators

Recruiting

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) (KEYSTONE-002)

Esophageal Squamous Cell Carcinoma

China
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

Esophagogastric Adenocarcinoma

Germany
Instituto de Investigacion Sanitaria La Fe
Karolinska Institutet; Medical University of Vienna; Ain Shams University; Medical... and other collaborators

Recruiting

Clinical Validation of Radiomics Artificial Intelligence: Application to Breast Cancer Treatment Planning (RADIOVAL)

Breast Cancer

Austria, Sweden, Turkey, Argentina, Croatia, Egypt, Poland, Spain

Search clinical trials for: Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations